Abstract LB-118: SR8541A is a potent inhibitor of ENPP1 and exhibits dendritic cell mediated antitumor activity
Alexis Weston(Translational Genomics Research Institute), Sunil Sharma(Translational Genomics Research Institute), Srinivas Rao Kasibhatla(Translational Genomics Research Institute), Trason Thode(Translational Genomics Research Institute), Ryan Rodriguez del Villar(Translational Genomics Research Institute), Mohan R. Kaadige(University of Utah), Srikanta Dana(Translational Genomics Research Institute)
Cited by 11
Related Papers
The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer
|PLoS ONE|2020|82
Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells
|Prostate Cancer and Prostatic Diseases|2016|47
MondoA-Mlx Transcriptional Activity Is Limited by mTOR-MondoA Interaction
|Molecular and Cellular Biology|2014|41
Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells
|Oncotarget|2018|27
Histone Deacetylase Inhibition Has Targeted Clinical Benefit in <i>ARID1A</i> -Mutated Advanced Urothelial Carcinoma
|Molecular Cancer Therapeutics|2018|24